Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Ahmet Aydin

Concepts (135)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Penile Neoplasms
7
2025
45
3.630
Why?
Urinary Bladder Neoplasms
7
2022
167
2.790
Why?
Carcinoma, Squamous Cell
5
2021
332
1.790
Why?
Carcinoma, Transitional Cell
3
2022
54
1.410
Why?
Prostatic Neoplasms
3
2020
401
1.400
Why?
Kidney Neoplasms
5
2021
181
1.390
Why?
Lymphocytes, Tumor-Infiltrating
3
2021
89
1.300
Why?
Carcinoma, Renal Cell
4
2021
112
0.910
Why?
Immunotherapy
6
2021
266
0.790
Why?
Pheochromocytoma
1
2023
34
0.790
Why?
Adrenal Gland Neoplasms
1
2023
49
0.780
Why?
Urothelium
1
2021
20
0.670
Why?
BCG Vaccine
2
2020
16
0.650
Why?
Neoadjuvant Therapy
5
2022
124
0.640
Why?
Indocyanine Green
1
2020
29
0.640
Why?
Cancer Vaccines
1
2021
79
0.630
Why?
Ubiquitin Thiolesterase
2
2021
17
0.620
Why?
CD8-Positive T-Lymphocytes
1
2021
145
0.620
Why?
Adjuvants, Immunologic
1
2020
52
0.610
Why?
Male
24
2025
27444
0.590
Why?
Anesthesia, Local
1
2019
18
0.590
Why?
Tumor Suppressor Proteins
2
2021
130
0.580
Why?
Edetic Acid
1
2019
14
0.580
Why?
Patient Readmission
1
2021
251
0.580
Why?
Testicular Neoplasms
4
2021
46
0.580
Why?
Immunotherapy, Adoptive
1
2021
163
0.580
Why?
Ureteral Neoplasms
1
2019
11
0.580
Why?
Prostate-Specific Antigen
1
2019
43
0.570
Why?
Papillomavirus Infections
1
2021
177
0.570
Why?
Oligopeptides
1
2019
94
0.550
Why?
Neoplasm Recurrence, Local
4
2021
647
0.520
Why?
Humans
30
2025
53246
0.510
Why?
Cystectomy
3
2022
52
0.500
Why?
Arteriovenous Fistula
1
2016
28
0.480
Why?
Neoplasms, Germ Cell and Embryonal
3
2021
21
0.430
Why?
Antineoplastic Combined Chemotherapy Protocols
4
2022
1043
0.410
Why?
Retrospective Studies
9
2022
6821
0.400
Why?
Middle Aged
11
2021
13422
0.390
Why?
Lymphatic Metastasis
4
2021
211
0.380
Why?
Aged
10
2021
10430
0.370
Why?
Neoplasm Grading
4
2020
128
0.360
Why?
Neoplasm Invasiveness
3
2022
281
0.350
Why?
Tumor Microenvironment
3
2021
274
0.310
Why?
Female
13
2023
28792
0.300
Why?
Lymph Nodes
2
2021
252
0.290
Why?
Treatment Outcome
7
2022
5597
0.260
Why?
Prognosis
3
2020
2118
0.230
Why?
Social Stigma
1
2025
52
0.230
Why?
Neoplasm Metastasis
3
2021
237
0.210
Why?
Postoperative Complications
3
2021
1099
0.210
Why?
Quality of Life
2
2020
902
0.200
Why?
Early Detection of Cancer
1
2025
190
0.200
Why?
Adrenalectomy
1
2023
31
0.200
Why?
Adrenal Glands
1
2023
38
0.200
Why?
Adult
8
2023
14541
0.190
Why?
Public Health
1
2025
231
0.190
Why?
Neoplasm Staging
3
2021
774
0.190
Why?
Deoxycytidine
1
2022
26
0.180
Why?
Aged, 80 and over
2
2021
3495
0.180
Why?
Retroperitoneal Space
2
2021
26
0.180
Why?
Cohort Studies
3
2021
1557
0.180
Why?
Muscles
1
2022
110
0.180
Why?
Mycobacterium bovis
1
2021
11
0.170
Why?
T-Lymphocytes
2
2020
320
0.170
Why?
Antigens, Differentiation, Myelomonocytic
1
2021
38
0.170
Why?
Lymph Node Excision
2
2021
132
0.170
Why?
Aftercare
1
2021
73
0.170
Why?
Teratoma
1
2021
22
0.170
Why?
Interleukin-2
1
2021
69
0.170
Why?
Reference Standards
1
2020
52
0.160
Why?
Tomography, Emission-Computed
1
2020
53
0.160
Why?
Fluorouracil
1
2020
59
0.160
Why?
Cisplatin
1
2022
282
0.160
Why?
Lymphocyte Activation
1
2021
163
0.160
Why?
Recurrence
2
2019
694
0.160
Why?
Carcinoma in Situ
1
2020
72
0.150
Why?
Antigens, CD
1
2021
217
0.150
Why?
Sentinel Lymph Node Biopsy
1
2020
119
0.150
Why?
Survival Rate
2
2019
949
0.150
Why?
Gallium Isotopes
1
2019
2
0.150
Why?
Gallium Radioisotopes
1
2019
9
0.150
Why?
Patient Discharge
1
2021
325
0.150
Why?
Kidney Pelvis
1
2019
16
0.140
Why?
Disease-Free Survival
1
2020
466
0.140
Why?
Feasibility Studies
1
2020
412
0.140
Why?
Genomics
1
2020
271
0.140
Why?
Papillomavirus Vaccines
1
2019
74
0.140
Why?
Urologic Neoplasms
1
2018
12
0.140
Why?
Ureteral Obstruction
1
2019
62
0.140
Why?
Carcinoma, Papillary
1
2018
50
0.130
Why?
Antineoplastic Agents
3
2020
1232
0.130
Why?
Genetic Predisposition to Disease
1
2020
533
0.130
Why?
Cells, Cultured
1
2021
1569
0.130
Why?
Biopsy
1
2019
600
0.130
Why?
Cell Proliferation
1
2021
1031
0.130
Why?
Gene Expression Regulation, Neoplastic
1
2020
868
0.120
Why?
Renal Artery
1
2016
32
0.120
Why?
Nephrectomy
1
2016
81
0.120
Why?
Time Factors
2
2020
2992
0.120
Why?
Urinary Tract Infections
1
2015
56
0.110
Why?
Prospective Studies
1
2020
2412
0.110
Why?
Laparoscopy
1
2016
180
0.100
Why?
Kidney Failure, Chronic
1
2015
210
0.090
Why?
Kidney Transplantation
1
2015
204
0.090
Why?
Risk Factors
1
2019
4018
0.080
Why?
Chemotherapy, Adjuvant
2
2020
122
0.080
Why?
Kaplan-Meier Estimate
2
2021
487
0.070
Why?
Follow-Up Studies
3
2020
2318
0.070
Why?
Survival Analysis
2
2021
659
0.070
Why?
T-Lymphocyte Subsets
1
2021
39
0.040
Why?
Immune System
1
2021
41
0.040
Why?
Administration, Topical
1
2020
62
0.040
Why?
Forkhead Transcription Factors
1
2021
120
0.040
Why?
Urinary Bladder
1
2020
101
0.040
Why?
Patient Selection
1
2020
273
0.040
Why?
Treatment Failure
1
2019
119
0.040
Why?
Macrophages
1
2021
380
0.030
Why?
Socioeconomic Factors
1
2020
623
0.030
Why?
Health Facilities
1
2017
40
0.030
Why?
Oncolytic Virotherapy
1
2017
28
0.030
Why?
Combined Modality Therapy
1
2018
640
0.030
Why?
Adolescent
2
2019
6912
0.030
Why?
Mutation
1
2021
1338
0.030
Why?
Turkey
1
2015
17
0.030
Why?
Clinical Trials as Topic
1
2017
466
0.030
Why?
Child
2
2019
7384
0.030
Why?
Graft Survival
1
2015
158
0.030
Why?
Cytokines
1
2017
627
0.030
Why?
Registries
1
2017
652
0.030
Why?
Antibodies, Monoclonal
1
2017
477
0.020
Why?
Mice
1
2020
5982
0.020
Why?
Child, Preschool
1
2019
4164
0.020
Why?
Young Adult
1
2018
4514
0.020
Why?
United States
1
2017
5413
0.020
Why?
Animals
1
2020
13528
0.010
Why?
Aydin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description